Form 4: Jazz Pharma Director Sells Shares for Tax Obligations

Kenneth W. O'Keefe, a director at Jazz Pharmaceuticals plc, sold 603 ordinary shares to cover tax liabilities from vested restricted stock units.

Summary

• Kenneth W. O'Keefe, a director of Jazz Pharmaceuticals plc, reported a transaction involving the company's ordinary shares.
• On December 2, 2025, O'Keefe disposed of 603 ordinary shares at a price of $173.07 per share.
• This sale was conducted to satisfy tax obligations incurred from the vesting of previously granted restricted stock units.
• Following this transaction, O'Keefe directly beneficially owns 25,811 ordinary shares.
• Additionally, 4,445 ordinary shares are indirectly beneficially owned through The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, where O'Keefe serves as both trustee and beneficiary.
• The filing also noted the cancellation for no value of 2,258 RSU shares on December 1, 2025.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations, which is neutral in terms of sentiment. It does not indicate a change in confidence or company performance.

Positives

• The transaction is a routine sale to cover tax obligations, not a discretionary sale indicating a lack of confidence in the company.

Negatives

• A reduction in direct beneficial ownership by 603 shares, although for tax purposes.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide broader industry context. It reflects an individual director's share activity rather than a company-wide strategic or financial update.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary sale by a director to cover tax liabilities, not indicative of a change in company fundamentals or outlook.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a director to satisfy tax obligations arising from vested restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamentals or the director's confidence in the company. Therefore, it provides no new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Stock Sale, Tax Obligations, Restricted Stock Units, Director Transaction, Kenneth O'Keefe